<DOC>
	<DOCNO>NCT03000946</DOCNO>
	<brief_summary>The purpose study determine whether somatostatin effective octreotide prevention post-pancreatectomy pancreatic fistula</brief_summary>
	<brief_title>Prevention Postoperative Pancreatic Fistulaby Somatostatin</brief_title>
	<detailed_description>Prevention pancreatic fistula remain major challenge surgeon , various technical pharmacological intervention investigate , conflict result . Despite several prospective study , metaanalyses , prophylactic role pancreatic fistula octreotide , remain controversial , even recommend routine use patient undergoing pancreatic resection . In view recent result , investigator hypothesize high affinity somatostatin-receptor lead stronger pancreatic exocrine secretion inhibition , well pancreatic fistula prevention . Consequently , continuous intravenous infusion somatostatin-14 , natural peptide hormone , associate 10 50 time strong affinity somatostatin receptor , associate improved pancreatic fistula prevention compare octreotide .</detailed_description>
	<mesh_term>Pancreatic Fistula</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Men woman age 18 year great Signed informed consent Candidate pancreaticoduodenectomy distal pancreatectomy without splenectomy Patient neoadjuvant chemo and/or radiation therapy Pregnancy Breastfeeding Patients liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis Patients abnormal coagulation ( INR &gt; 1.5 ) patient receive anticoagulant affect PT ( prothrombin time ) APTT ( activate thromboplastin time ) Patients WBC &lt; 3 X 109/L ; PLT &lt; 100 X 109/L Patients current prior medical condition may interfere conduct study evaluation result opinion Investigator Patients participate clinical investigation investigational drug within 1 month prior inclusion Known hypersensitivity somatostatin somatostatin analogue component somatostatin octreotide LAR s.c. formulation Patient previously treat somatostatin somatostatin analogue component somatostatin octreotide LAR s.c. formulation Patients treat ciclosporin Patient without health insurance social security Patients history noncompliance medical regimen consider potentially unreliable unable complete entire study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pancreatectomy</keyword>
	<keyword>Somatostatin analogue</keyword>
	<keyword>Octreotide</keyword>
	<keyword>Pancreatic fistula</keyword>
</DOC>